ESMO 2024 Highlights in Thoracic Oncology: Dr. Molly Li Shares Insights

Molly Li, MBBS, of the Chinese University of Hong Kong, shares highlights in thoracic oncology from the European Society of Clinical Oncology (ESMO) 2024 Congress.

“ESMO has always been one of my favorite conferences to attend… it’s a great platform for us to exchange new information and ideas,” Dr. Li said.

Dr. Li spoke about important data presented at the ESMO 2024 Congress, which was held in Barcelona, Spain. He discussed the Canadian Cancer Trials Group BR31 study titled “A double-blind, placebo-controlled, randomized phase 3 trial of adjuvant durvalumab in completely resected non-small-cell lung cancer” and the implications of the study, which did not meet its primary endpoint.

“The main point of it is that it highlighted in such cases the neoadjuvant perioperative role would certainly take over the adjuvant immunochemotherapy as the standard of care, and for future studies, we should more use of the neoadjuvant and perioperative studies as the benchmark,” Dr. Li said.